FUNDAMENTAL PRINCIPLE AND APPLICATIONS OF IONTOPHORESIS IN CONTEMPORARY ADVANCEMENT OF DRUG DELIVERY SYSTEM: A CRITICAL APPRAISAL

FUNDAMENTAL PRINCIPLE AND APPLICATIONS OF IONTOPHORESIS IN CONTEMPORARY ADVANCEMENT OF DRUG DELIVERY SYSTEM: A CRITICAL APPRAISAL

Om M. Bagade * and Priyanka E. Doke

Department of Pharmaceutics, Vishwakarma University School of Pharmacy, Pune, Maharashtra, India.

ABSTRACT: The skin is the human body's biggest organ, with a surface region of around 2 m². Generally, the skin was seen as an impermeable boundary. Yet, as of late, it has been progressively perceived that unblemished skin can be utilized as a port for the topical or ceaseless foundational organization of medications. For drugs that have short half-lives, a transdermal course gives a consistent method of organization, to some degree like that given by intravenous implantation. In contrast to intravenous implantation, the passage is non-intrusive, requiring no hospitalization. A method of reasoning to investigate this course exists just for medications exposed to a broad first pass digestion when given orally or those that must be taken a few times each day. That being said, just powerful medications can be directed through this course since there are monetary and restorative motivations not to surpass the fixed estimate past a specific farthest point. Sedate transportation has recently been confronted with two significant challenges. The first is achieving zero request arrival of pharmaceuticals for extended periods. The second is pulsatile or triggered medication discharge, which is the regulated arrival of medications in response to a boost. Polymer-based controlled drug transportation frameworks are becoming increasingly popular due to their ability to maintain pharmaceutical concentration.

Keywords: Iontophoresis, Transdermal route, Stratum corneum, Permeation enhancer, Electrically based drug delivery

INTRODUCTION: Focus on the medication to a specified body zone throughout an optimum period with only a single chunk, minimize the requirement for follow-up consideration and increase persistent consolation and consistency ¹. Although these controlled discharge frameworks offer advantages over standard pharmaceutical delivery frameworks, they are not responsive to altering physiological situations.

As a result, perfect medicine conveyance frameworks are required, which can react to changes in physiological situations and adjust sedate discharge designs accordingly ². Medicate delivery for a beat or self-directed instruments should be advanced. The importance of medication delivery frameworks, which mimic the symptomatic requirement of infection, has been discovered by understanding the concept of chronopharmacology and variations in illness indications.

According to continuing research, the time of therapy is also a key impact on the delivery of medications into the body ^{3, 4}. These ideas have led researchers to focus on developing more responsive medicine delivery systems, in which the right amount of medication is delivered to the right site of activity in the body at the right moment ⁵.

Novel Drug Delivery System: The novel drug delivery system (NDDS) is being considered to modify the body dispersion of drugs to decrease medication lethality and/or deliver them more effectively to their activity site or to increase the remedial list. A lot of research was done on how the medicine stages could be altered and reached out to find more aids and lessen the toxicological hazards associated with the dose of medication ^{6, 7}.

As a result, novel conveyance frameworks for non-traditional organizational courses of action were considered, built, and tested ⁸. Various modern improvements, including focusing on ideas, have appeared for the effective conveyance of bioactive over the last three decades. These cutting-edge innovations have overcome the limitations, providing feasible nearby and basic medicine stages at looked-for destinations with better health profiles. The augmented focus on patient consistency and decrease in portion recurrence has managed to expand a new and appealing technique of administering prescriptions, which is to administer them through the skin ⁷. Patients regularly fail to take their prescriptions, and even the most dependable of patients grow tired of swallowing tablets, especially as a daily measurement. Skin is one of the most diverse and easily reachable organs in the human body. Restorative mixes are coupled to the skin in advanced pharmaceutical practice for dermatological (inside the skin), neighbourhood (territorial), and transdermal (foundational) delivery. The stratum corneum is the principal barrier to medicine penetration in transdermal delivery ⁹. Various approaches for improving entrance are used to avoid the stratum corneum and broaden the transition through the skin film. The skin attends as a conduit of entrance into the body for pharmaceutical administration, allowing for incessant transdermal imbuement into the fundamental dispersion ¹⁰. As previously said, it is a standout among the human body's broadest and most readily accessible organs. As the body's largest and most visible organ, the skin has unparalleled significance in expressing a person's state of being ¹¹. A conveyance system is required to deliver helpful specialists to fundamental flow through the skin. Several medication conveyance instruments utilize optional forms of vitality to encourage medication pervasion through the skin. The transdermal drug delivery system (TDDS) was created for topical administration into the faultless skin external to provide consistent medication imbuement through unblemished skin. This can provide medications to patients via a skin portal for basic distribution. Conveyance via the transdermal route is an intriguing option in this regard because it is both advantageous and safe.

A System for Delivering Medications Through the Skin: "The transdermal drug delivery framework/system (TDDS) can be well-defined as a conveyance device that, when applied to an appropriate skin exterior, will almost certainly deliver the medication at a measured rate into the foundational flow at clinically adequate focuses to confirm long-term biological viability ^{12, 13, 14}.

FIG. 1: SIGNIFICANCE OF IONTOPHORESIS AS DIFFUSION

As a result, percutaneous retention is defined as the entry of material into various layers of the skin and saturation of the skin into fundamental dissemination ¹⁵. Iontophoresis, as seen in Fig. 1 is one method for getting through the stratum corneum obstacle. The percutaneous assimilation procedure is a stage-appropriate procedure that includes ¹⁶:

1. Penetration: A substance's entry into a certain layer.
2. Permeation: The transition from one unique layer to another, both practically and structurally distinct from the primary layer.
3. Absorption: The process of a substance being absorbed into the fundamental flow.

Transdermal Therapeutic Systems:

New Methods: Novel medication conveyance frameworks are newer measurement structures and medication conveyance frameworks that provide significant improvements in medication treatment (NDDS). These are called 'novel' since they are still being developed with good consequences in medicine transport ¹⁷. The chief purpose of NDDS is to confirm drug security besides appropriateness, and patient consistency ¹⁸ Fig. 2 is an example of a revolutionary developed transdermal development.

FIG. 2: NOVEL ADVANCED TRANSDERMAL TECHNOLOGIES

Further than iontophoresis, other improvements like ultrasonography, concoction enhancers, and electroporation have remained used to improve transdermal medicine transfer. For TDDS, the subsequent combined iontophoresis systems have been employed ¹⁹:

1. Iontophoresis + Chemicals
2. Iontophoresis + Ultrasound and

III. Iontophoresis + electroporation

The inability to deliver new biomechanical components such as peptides, oligonucleotides, and small proteins is one of the synthetic enhancers' drawbacks. As a result, the resurgence of curiosity appeared to be geared toward the advancement of another intriguing strategy, iontophoresis, which was developed in the last decade ²⁰. The iontophoretic approach is useful for increasing the transdermal distribution of peptides and proteins with a lesser ebb and flow power in a short interval. Iontophoresis is defined as "the pervasion of ionized medication particles crosswise over natural films affected by electrical flow" or "a method for transporting ionic or exciting atoms into tissue by a section of immediate or intermittent electric flow via an electrolyte arrangement comprising the ionic atoms to be conveyed using a proper cathode extremity ²¹. By transmitting DC electrical flow between two terminals, particles in an account are transferred via the skin. Iontophoresis refers to the use of a little amount of physiologically appropriate electric flow (0.5 mA/cm² or fewer) to push ionic (charged) medications into the body using a cathode of the same extremity as the medication's charge. Electrostatic repulsion slams the medicine into the skin. For reaching, anticipating any skin consumption, defeating skin opposition, and shielding the skin since keeping any scorching metallic complex framed on the metal plate exterior, a soggy cushion between the anode plate and skin is essential ²². The technique has been shown to improve the transdermal pervasion of ionic pharmaceuticals by a few overlays and has prolonged the prospect of transdermal regulator tranquillizing conveyance for basic prescription ²³. In addition to the benefits of TDDS, iontophoresis offers a one-of-a-kind opportunity to provide tailored medication. This is because the pervasion rate directly depends upon the existing thickness, which can be quickly balanced. Because of this dependency on current medication, assimilation by iontophoresis may be less susceptible to natural variables. While each of these enhancers has been shown to boost transdermal drug passage, their combined effects are now thought to be more effective than each of them individually.

Iontophoresis: The stratum corneum serves as a guideline for drug retention through the skin, limiting the diffusion of hydrophilic, high-atomic-weight, and charged mixtures into the fundamental course. However, many therapeutically active pharmaceutical particles, such as peptides, are aqueous and have larger atomic loads ²⁴. Iontophoresis is defined as the use of small amounts of physiologically acceptable electric flow to deliver ionic (charged) medicines into the body ^{25, 26}. It is a non-invasive method that uses a low-voltage electric current to improve and stimulate the transdermal delivery of various medicines ²⁷. Electrostatic shock is used to crush the medication into the skin, with the anode of the same dimension as the charges on the medication ²⁸. Aside from the benefits of avoiding hepatic first-pass digestion and improving patient consistency, it also has some additional features, such as the conveyance of ionized and unionized medications, enabling constant or pulsatile medication conveyance, allowing simpler end-of-medication conveyance, reclaiming the skin boundary without causing serious skin irritation, improving the conveyance of polar atoms as well as high sub-atomic weight mixes and the ability to be used in combination. Because the rate of medication conveyance is more dependent on connected current than on stratum corneum qualities, it can be used for foundational or neighbourhood (topical) medication conveyance, giving better control over the amount of medication conveyed and narrowing the gap between independent and intra-singular changeability. As a result of several beneficial situations associated with this framework.

It has been a source of growing interest in the community and the essential delivery of a variety of medications. The iontophoretic method is based on the electrostatic shock principle that "like charges repel and inverse charges attract." The drugs get beyond the skin barrier with a simple electronic shock of similar charges. A negatively charged functioning cathode allows anionic drugs to pass through the skin in this way. When a strongly charged terminal administers cationic drugs, they are more likely to penetrate the skin. It is placed between the negative anode (cathode) and the skin while transporting anionic medicine transverse over the organic film. The electromotive power of the cell then pulls the medicine particle through the skin to the positive terminal (anode). If cationic medication is required, the endpoint polarities are inverted. Fig. 3 depicts the component of iontophoresis.

FIG. 3: IONTOPHORESIS MECHANISM

When the drug has passed it through the stratum corneum, it swiftly enters the dispersion phase and travels to its site of action. The formation of endogenous counter particles inside the skin completes the electric circuit. In-vitro iontophoretic ponders based on peptides have shown that the skin's latent porousness expands after iontophoresis. This reveals that one of the components for improved porousness following iontophoresis is the alteration of the skin boundary work due to the current section in-vitro ²⁹. Due to various electroosmotic and osmotic powers on electric flow utilization, neutral atoms have been observed moving via convective stream ³⁰.

Electro assimilation occurs when a voltage difference is linked over a charged, porous film. This stream contains liquid movement without a focal angle, and it has a significant impact on iontophoresis. Human skin has a small negative charge at physiological pH; therefore counter particles are generally cations. Streaming occurs electro osmotically from anode to cathode in this manner, improving the mobility of cationic medicines. Although traditional iontophoresis uses a constant DC current, beat waveform DC has also been used, which has the ability to create large and rapid drug delivery; for example, infiltration of thyrotrophic discharging hormone (TRH) was significantly higher when given by beat structure than when given by constant current ^31-33. A beat waveform allows the skin to depolarize and return to its natural state before the next heartbeat begins. This is because the stratum corneum functions as a capacitor and polarization can reduce the amount of currently linked as a constant current. Furthermore, the beat waveform prevents the skin from generating polarization potential, reducing the efficiency of iontophoresis. Unlike beat waveform direct current, direct current produces changeless polarization, resulting in a decrease in iontophoresis effectiveness. Furthermore, beat current is less harmful to the skin, allowing patients to tolerate higher current levels when beat DC with a high recurrence is used ^34-37.

Iontophoretic Treatment Standards: Iontophoresis uses an electric flow to increase the entry of electrically charged medicines into surface tissues ³⁸. According to the fundamental electrical principle of "similar charges repel one another and inverse charges attract in," electrical vitality aids particle formation over the stratum corneum. The medication is attached to an anode with a similar charge to the medication. A nonpartisan spot on the body surface is used as an arrival cathode that is reversed in control of the drug. The administrator then selects a smaller current than the patient's pain threshold and allows it to flow for the appropriate amount of time. By repelling like charges and attracting inverse charges, the electrical flow aids in drug penetration into surface tissues. The medication must always be charged (or altered to communicate a charge). The illness method must be performed at or near a body surface area the two typical requirements for iontophoretic medicines.

Mechanisms and Devices for Iontophoresis: A typical iontophoresis device consists of a DC voltage conveyance system and terminals. The unit is then wired to the interactive and uninvolved anodes, and the current and time are set in the unit Fig. 4. The current starts at the gadget and is exchanged as an ionic stream from the anode through the ionized pharmaceutical arrangement in the iontophoresis procedure. The medication particles are transported to the skin, where the repugnance continues to transport the medication through the watery pores of the trans-appendageal components and stratum corneum interstices ³⁹. The greater the cathode area, the more the ebb and flow that the device must provide to include a momentum thickness for moving the drug.

Three Systems Improve Transdermal Drug Delivery with Iontophoresis:

• Cooperative ion-electric fields provide additional power to propel particles through the skin.
• The electric current increases the skin's penetrability and
• Electro-assimilation causes dissolvable mass movement, which carries particles or nonpartisan entities along the solubilized stream.

The electroosmotic stream is analogous to the flow of counter-particles in that it occurs in layers. It could either aid or hurt medical transport. Counter particles are certain particles and electroosmotic stream occurs from anode to cathode, since human skin is negatively charged above pH 4. Anodic conveyance is aided by electro-assimilation, but cathodic conveyance is hampered.

FIG. 4:  IONTOPHORESIS MACHINE

Transdermal conveyance of a large anion (adversely charged protein) from the anodic chamber is much more compelling than that from the cathode chamber due to the electroosmotic stream ⁴⁰. Power, batteries, or battery-powered power sources can all be used to control iontophoretic devices. Electric-powered equipment are available in India. Drionic, Phoresor and other battery-operated machines are examples. A Phoreser device consists of a battery-powered DC current controlled by a microprocessor and a medication repository and cathodes depicted in Fig. 4.

The batteries are almost always 9 volts. The drug supply is made up of a bandage/fabric or gel padding to which the arrangement is attached, or the configuration is infused into the storage anode mix through a port.

The microchip component and the static and detachable anodes are connected via wires. Iomed iontophoretic medicate transportation cathodes are available, and they're made of hydrogel substance that needs to be hydrated before use to deliver local anesthetic.

Characteristics of Iontophoretic Devices: The cathodes, sedate reservoir, and power supply are the main components.

Electrodes: The anodes are responsible for converting electronic electricity to ionic currents. The contributor line is connected to the pharmaceutical supply, while the helper anode is connected to the counter store, which provides a path for the current to travel. No consumable or incapacitated terminals (treated steel and platinum) and consumable or activated anodes (silver and silver/silver chloride) have been assigned.

Power Source: In most iontophoretic tests, fairly constant immediate current (DC) transdermal iontophoresis is used; however, it has been discovered that when using DC strategies, there is a large medication movement-wide range with moment and skin-to-skin inconstancy of medication focus when compared to some other sustained conductance substituting current (AC).

Medication motion remained increasingly consistent during the constant conductance AC iontophoresis, and skin-to-skin variation was significantly reduced. The persistent conductance AC iontophoresis movement studies suggest that this method successfully maintains the layer parameters that affect transport at a constant state, allowing for a generally stable and long-lasting motion ^{41, 42}. Iontophoretic tests are frequently performed at current densities less than 0.5 mA/cm-2 to avoid skin damage.

Reservoirs of Drugs: This program has made use of several different pharmaceutical repositories. The same antecedents are given: Poly (ethylene oxide), PEO polymer electrolyte ionically leading polymers, also known as polymer electrolytes, are potential rivals as hosts for iontophoretically delivered pharmaceuticals. Utilizing lithium chloride or lidocaine hydrochloride as prototype pharmaceuticals, thin, completely solid polymer electrolyte sheets were produced from poly (ethylene oxide) (PEO). Iontophoretic transport of lithium chloride and lidocaine hydrochloride was proven in tests using these PEO-based pictures.

For PEO-based pictures, cation transport number assessments provide esteems of around 0.4 for lithium chloride structures and 0.12 for lidocaine hydrochloride systems. The transport component of these PEO-based polymer electrolyte films allows the conveyance of ionic salts such as lithium chloride and lidocaine hydrochloride to be regulated only by the current, resulting in a framework that can deliver precise amounts of medication ^{43, 44}.

PVP stands for poly (vinyl pirrolidone): PVP is a water-soluble polymer used to develop hydrogels with chitosan ⁴⁵, poly (styrene-co-N-dimethylamino ethyl methacrylate) composite microspheres ⁴⁶, polyacrylic corrosive semi-interpenetrating systems ⁴⁷ and hydroxypropyl methylcellulose. When compared to a single polymer vehicle, the presence of PVP in a double framework appears to increase tranquillize penetrability ⁴⁸.

Poly (Vinyl Liquor) – PVA: Rehashed solidify defrosting cycles using fluid arrangements of PVA samples can be used to create cross-linked poly (vinyl liquor) (PVA) hydrogels ⁴⁹. When used as a medicinal substance, PVA dissolves in water and has focal points. Polyvinyl liquor (PVA), poly (ethylene glycol) (PEG), and cross-connected polyacrylamide (PAM) chains have been proposed as a viable supply for regulated delivery of macromolecular drugs such as insulin ⁵⁰. A diclofenac sodium controlled-discharge arrangement for the transdermal organization has been developed. A dissolvable tossing technique was used to create poly (vinyl liquor) (PVA) and PVA/poly (acrylic corrosive) (PAA) compound layers using different PVA/PAA (v/v) proportions. Under in vitro settings at pH 7.4, the arrival of the drug from the film was evaluated, and the transportation framework provided additional release devoid of time slack, burst impact, or limit layer opposition.

Drug Delivery and Iontophoretic Research: Iontophoresis was presented as a physical treatment for improving skin penetration. A significant portion of the drugs indicated that there was not quite enough skin porousness in uninvolved assessments. The transdermal pervasion of medication particles is influenced to a large extent by the outflow characteristics of medication from utilization and the construction of the medication conveyance framework ^{51– 53}. Natural solvents and dynamic surface experts can also promote percutaneous retention by changing the penetrability of skin.

As the medication release rate from the medication conveyance framework increases, so does the transdermal saturation rate. The following are important components of improving drug mobility through the skin:

• Iontophoresis is a type of iontophoresis that involves (electro repulsion, electromigration, or Nernst board impact).
• Stream electroosmotic.
• The impact on the environment (current instigated increment in skin pervasion).

Iontophoresis uses two main processes to increase tranquilizer delivery across the skin: electro repulsion and electro-osmosis. The instantaneous influence of the coupled electric field on a charged permeant is known as electron repulsion. The second device, electro-osmosis, is based on the skin's ability to maintain a negative surface charge at physiological pH ^{54, 55}.

Iontophoresis is a non-intrusive technique for assisting high centralization of a charged substance, most commonly medicine or bioactive agents, transdermally by undesirable electro-rational power utilizing a small electrical flow attached to an iontophoretic chamber containing a similarly charged dynamic expert and its vehicle.

The positively charged chamber, known as the anode, will repel an eloquently charged substance into the skin. In contrast, the negatively charged chamber, known as the cathode, will repel an adversely charged substance into the skin. Electro-movement and electroosmosis are the dominant forces in mass transportation when an electric field is visible ⁵⁶.

These changes are measured in synthetic transition units, usually mol/cm2 h. This method is based on the principle that similar charges repel each other. Suppose delivery of a strongly charged medication (D+) is required during iontophoresis. The charged drug is torn up in the electrolyte surrounding the endpoint of comparative extremities, such as the anode in this example ⁵⁷. When an electromotive force is applied, the drug is repelled and moves over the stratum corneum to the cathode, placed elsewhere on the body. The cathode-cathode correspondence around the outside skin is irrelevant; for example, the creation of medicine particles between the anodes occurs via the skin rather than superficially. When the cathode is placed in the donor compartment of a Franz dissemination cell to help an anion go faster, it’s called cathodal iontophoresis.

The situation would be reversed for anodal iontophoresis. Iontophoresis uses a low current, and patients experience little to no feeling during the procedure ⁵⁸.

FIG. 5: IONTOPHORETIC TECHNIQUE: DRUG CATIONS ARE REJECTED AND TRAVEL THROUGH THE SKIN AS CURRENT IS ADMINISTERED, EVENTUALLY BECOMING CAUGHT UP IN THE FUNDAMENTAL DISSEMINATION

Fig. 5 depicts the basic devices for ionic/subatomic transport over the skin using iontophoresis. Because like charges repel one another, the charged particle is repelled by a cathode with a similar charge and consumed through the skin. The skin, which is negatively charged at physiological pH, acts as a cation-specific film that promotes cation formation via anodal iontophoresis. In light of the production of counter particles, anodal iontophoresis also generates laminar movement of the dissolvable. Electro osmosis is a process that involves the movement of neutral mixtures as well as positively charged particles. Various attempts have been made to characterize the pace of iontophoretic conveyance due to the complicated concept of iontophoretic transportation. To compare the iontophoresis movement with electric transportable, electro osmosis, and fundamental dissemination, Abramson and Gorin extrapolated a condition would be included in the expanded transition during iontophoresis ⁵⁹.

• Flux as a result of the electrical gradient angle passing through the skin;
• Changes in skin porousness as a result of the electric field and
• Dissolvable drag caused by an electroosmotic water stream

Jelectric + Jpassive + Jconvective = Jionto Jelectric The motion caused by the application of electric flow; Jpassiv. The transition is caused by inactive conveyance via the skin and Jconvective. The motion caused by convective transport is caused by electro assimilation.

Because the first condition does not have a term for the convective electroosmotic stream, the Nernst-Planck condition has been modified to predict iontophoretic improvement proportions (proportion of relentless state motion close to electric potential and without potential) largely focused on the commitments of the osmotic stream and merged this reality into a few conditions ^60-62.

Iontophoresis Molecular Transport Pathways: Three basic paths can all give outcomes at the same time with percutaneous retention^{63, 64}.

• Intercellular (paracellular) communication between comeocytes.
• Transcellular (intracellular) communication between cells.
• Shunt route hair follicles, sweat ducts, and secretory organs.

FIG. 6: PATHWAYS OF MOLECULAR TRANSPORT IN IONTOPHORESIS

Particles are drawn to the shunt pathway's paths. The physiochemical characteristics of medication particles influence drug appropriation. Fig. 6 depicts the drug will be limited in hair follicles by hydrophilic atoms in general. On the other hand, lipophilic atoms are mostly circulated in the lipid intercellular sections of epidermal keratinocytes' lipid layer and the stratum corneum. As a result, transdermal iontophoresis should be referred to as electrically assisted transdermal conveyance. A voltage contrast over a charged screen initiates an electroosmotic stream, a single-direction stream of counter particles, for example, from anode to cathode. Cathodic transportation of anions is thwarted as a result and anodic passage of cations is aided. Wrong-way iontophoresis occurs when the transport of a large anion from either the anodic segment seems to be more productive than the conveyance from the cathode. The electro repulsion effect improves the transition of small lipophilic cations the most ⁶⁵.

Iontophoresis as a medicine delivery system: This method's potential has been abused for the transdermal delivery of a variety of drugs with poor entrance properties, such as greater atomic weight electrolytes like proteins, peptides and oligonucleotides and that are normally difficult to manage other than by parenteral administration.

It also has a lot of potential for delivering charged peptides, which can be used as therapeutics. Even though iontophoresis had demonstrated a significant increase in the transdermal absorption of a variety of drugs, it has yet to demonstrate critical saturation of larger peptides such as insulin ⁶⁶.

The following are the Components of an Iontophoretic Drug Delivery System:

• An electronic current power source usually consists of a charge and controlled devices.
• A dynamic repository that includes the useful ionic operator; and
• An unattached or return repository structure consists an electrolyte and completes the electric circuit.
• There is also a control mechanism to monitor the overall procedure.

FIG. 7: THE IONTOPHORETIC SYSTEM

When the dynamic and indifferent store frameworks are installed on the skin, the current source sends electronic current to the dynamic repository, which is converted into ionic current. The ionic current travels from the dynamic repository to the skin, beneath the skin to the disinterested supply, and back to the unconcerned store. It is transformed back into the electronic current at the passive repository, completing the circuit at the opposite shaft of the current source which is depicted in Fig. 7 ^{66, 67}.

Iontophoretic System Types ^{68, 69}: Fig. 8 depicts the arrangement of medicine delivery using iontophoresis can be categorized in terms of the changes and improvements made to this framework, which allows for consistent and predictable medication delivery in a compelling manner.

FIG. 8: IONTOPHORETIC SYSTEMS OF SEVERAL SORTS

Iontophoresis in Reverse: Reverse iontophoresis, a technique in which a low electric current is used to pull intestinal fluids via the skin, is commonly used in analytic devices nowadays. This provides an excellent and non-intrusive technique for evaluating bodily liquids, allowing for the quantitative determination of the ideal material in the physiological liquid and hence effective screening. The turnaround iontophoretic process is used to continuously monitor the glucose level in the blood, such as with Glucowatch®. This system uses an electrical signal to correspond to the amount of glucose in the extracellular liquid and provides a needleless technique for verifying blood glucose levels in diabetic patients.

This makes it possible to extract phenylalanine quickly and directly and identify diseases like phenylketonuria using basic tools like biosensors. This process allows for unobtrusive examination as well as the production of isolated samples devoid of large atoms. In whatsoever case, this way makes inspecting less tedious. Because the amount extracted is so small, it requires a delicate investigative technique to be fruitful. Caffeine, theophylline, lithium, and phenytoin, for example, have all successfully used this tactic.

Iontophoresis Pulsatile / Switching: Several studies have been conducted in which, instead of using constant DC iontophoresis, DC as brief heartbeats have been used ⁶⁹.

Combination of Iontophoresis and Electroporation: Iontophoresis can also be used in other ways for enhancing skin infiltration, such as electroporation, which involves using voltage output (> 100 V) beats for a short period of time (s-ms) to increase penetrability into the skin. Iontophoresis is preceded by electroporation, which leads to the formation of permeablized skin as a result of exposure to high cardiac voltage ⁷⁰.

When used following electroporation, iontophoresis aids in broadening the skin's permeablized condition, resulting in a quick start (which is a drawback of iontophoresis alone) and an occasionally expanded transition ⁷¹. Enhanced transport by electroporation was induced by the creation of electro pores, just as a neighboring field-induced electrophoretic float. Tooth et al. investigated the impact of electroporation on buprenorphine conveyance and discovered that using 300 V or 500 V beats increased buprenorphine motion by a few folds over detached transport ⁷². Drugs including Salmon calcitonin (SCT) and, PTH mix; Tacrine hydrochloride have been successfully used with this methodology.

Drug Candidate Determination Criteria: The transdermal route of pharmaceutical administration has a number of drawbacks that make it unsuitable for a wide range of medications. Selecting suitable applicants is a critical step toward completing transdermal research ^73-77.

The following Characteristics should be Present in a Perfect Brand Drug for Effective Delivery by this method:

• A TDDS should not cover an area larger than 50 cm² and a daily portion of a pair of mg is required.
• The medication's successful grouping should be low, perhaps in the ng/ml range.
• The medication's half-life (t^1/2) should be short.
• There should be no skin irritants or dangers from the dynamic fixes.
• Because medication dispersion through polymers, like skin, is affected by the atomic size, medications with small subatomic sizes are preferred.
• The drug should have a lower softening point in order to keep up with normal body temperature.
• Drugs that degrade the gastrointestinal system or are neutralized by hepatic first-pass effect are viable options for transdermal delivery.
• Resistance to the drug must not develop due to transdermal conveyance's near-zero-request discharge profile.
• Before being separated into the aqueous reasonable tissue, the applicant drug must have adequate hydrophilic and lipophilic equilibrium to overcome the lipid impediment of the stratum corneum.

Points of Interest ⁷⁸:

• When properly connected, the method is simple.
• This process transports ionized and unionized medicines and is an alternative to infusion. It improves polar atom and large sub-atomic weight mix transport.
• The risk of infusion is reduced because therapy with this device is non-intrusive.
• It is less time-consuming.
• Because the drug conveyance rate depends on linked current, it reduces the risk of tissue harm and inconstancy between people.

Iontophoresis Strategy: There could be a difference between the amount of medication in the device and the amount that actually passed the skin. The gadget and innovation determine the amount that a device can fit, whilst the amount which crosses the skin is determined by definition and treatment. It is necessary to select the charged medicament. Electro-assimilation and iontophoresis could be used to transfer nonpartisan atoms. Following up on it, the charged atoms have two powers: electro repulsion and electro-assimilation, which stimulates medication to penetrate the skin. For the most part, liquid or gel detailing is suitable for iontophoresis. The gel is reasonably detailed in that it fits the skin's shapes and is stable. Gels also have advantages over fluids, such as ease of incorporation into the device, compatibility only with anode structure, deformability into skin shapes, improved resistance, and soundness. Furthermore, the high amount of water in the gel plan can provide an electro-conductive base for therapeutic usage ^{79, 80}.

In iontophoresis, how do You Define Dose: The dose for iontophoresis is calculated in milliamp-minutes because it is dependent on the current, which is the type of dose. Iontophoresis treatment is set to provide a current (for example, 2 mA) to the patient for a short period of time (for example, 10 min session or 20 mA min measurements). Anode arrangements typically have a capacity of 1.5 mL and a fixation of 2-5 percent. Using microchip and suitable hardware, the organization can be continuous or bolus. Because the amount of medication delivered is controlled by the current, the organization can be adjusted to quickly deliver the bolus part, followed by a mild support component over an indefinite time frame.

Challenges in Delivery: The most important goals in iontophoresis are to ensure that the correct portion is delivered during the dosage interval, that the system is secure, that it is followed properly, and that it isn't chafing. The third purpose is to create an extensive, cost-effective, and acceptable product to patients. To achieve these objectives, proper planning is essential. Occasionally, the pH of the skin layers’ changes, and the charged on the intrigue particle changes as it passes through the skin, enabling drug to fail to transit the skin. To appreciate the physical and chemical properties of the drugs, extensive preformulation is required ⁸¹. The cost of the device could be reduced by using reusable frameworks in which the hydrogel cushioning can be replaced with another. To keep costs down, a chip from a disposable device can also be used in another system.

Applications:

Hyperhidrosis: Hyperhidrosis is a common problem that can be embarrassing in social situations ⁸². Plantar and palmar hyperhidrosis are the most common conditions for iontophoresis.

In this therapy, the impacted area is soaked with tap water and the momentum is maintained at a high level just beneath the edge for convenience for about half an hour. The methodology is thought to be safe and effective ⁸³.

Cystic Fibrosis Analysis: Iontophoresis devices have also been used to diagnose cystic fibrosis. Iontophoresis devices are medical devices that have been approved for the diagnosis of cystic fibrosis using pilocarpine iontophoresis. Pilocarpine has a stimulating effect on eccrine discharge, whose chloride substance is used to aid in cystic fibrosis diagnosis. The procedure is presently well acknowledged as the safest and least upsetting method of energizing perspiration. The FDA has approved the use of pilocarpine iontophoresis to diagnose cystic fibrosis, and it is commonly used by pediatricians ⁸⁴.

Anesthetic: Local anesthesia is frequently necessary for superficial injury extractions, local skin biopsies, eyelid surgery, unpleasant entry point, or in individuals who are allergic to hypodermic needles. Torment, tissue bending, and probable basic assimilation are some of the drawbacks of administering a local sedative. The usefulness of iontophoresis for achieving local anesthetic has been well documented. No tissue deformation, sufficient proximity and small structural convergences of the drug are among the advantages of iontophoresis-induced anesthetic, and the technique is simple. Gangarosa declared that skin anesthesia was best obtained with arrangements including 1 percent and 4 percent lidocaine, with the expansion of epinephrine delaying the length of anesthesia, based on a controlled report employing lidocaine ⁸⁵.

Aiding Fundamental Depth of Tissue Infiltration of Intensifiers: Iontophoresis will be quite effective in the treatment of osteoarthritis, tender tissue ailment, tendonitis, as well as other deep developed adjacent incendiary conditions related to games wounds or other smaller coincidental wounds. Dexamethasone enters tissues beneath the linked site in monkeys, according to Glass et al. ⁸⁶. The drug was detected at sufficient tissue depths, including tendinous components and cartilaginous tissue. Some experts demonstrated iontophoresis of aqueous dissolvable gluco-corticoids dexamethasone, hydrocortisone and prednisolone up to a depth of 1.25 cm beneath the skin ⁸⁷.

Applications in Active Recuperation: Cortico-steroids are the most commonly used drugs in active recovery with iontophoresis. Corticosteroids are commonly used because they have a strong calming effect and are available in small doses for oral and topical administration. A few corticosteroids are available as water-solvent salts, which make the corticosteroid atom negatively charged and thus susceptible to negative momentum field movement. In treating musculoskeletal problems, dexamethasone is commonly administered through iontophoresis in combination with lidocaine.

The positive anode has been used to control this corticosteroid for a long time (Because it is a negatively charged particle, it is most likely assisted through the skin by an electroosmotic impact). DeLacerda used dexamethasone (1 mL of 0.4 percent dexamethasone mixed with 2 mL of 4 percent lidocaine in a fluid state aimed directly from either the anode at a quantification of 5mA for 10 minutes) to seek treatment with myofascial bear aid syndrome and discovered that iontophoresis produced the most rapid improvement in range of motion when compared to ultrasound or muscle relaxants. He used a 5 mA current for 15 min, coupled to trigger points ⁸⁸. Iontophoresis-controlled glucocorticoids have also been used to treat patients with temporomandibular trismus and paresthesia and Peyronie's disease ⁸⁹.

Physical Therapy's Genuine Applications Hyaluronidase: Hyaluronic corrosive, a dense material found in many biological tissues, is an important component of connective tissues' "ground substance."

It prevents specific chemicals from dispersing throughout the tissues. Hyaluronidase is a catalyst that degrades the integrity of hyaluronic acid by hydrolyzing it ⁹⁰. At a pH of 5.4, hyaluronidase has a positive electrical charge and moves the fastest. As a result, it is coupled to an edematous appendage by iontophoresis in a 0.1-mol/L configuration with an acetic acid derivation support ⁹¹.

Vasodilators: Iontophoresis has been used to modulate two powerful vasodilators, histamine and mecholyl (acetyl-beta-methyl choline chloride), for a variety of disarrays. Kling and Sashin investigated the effectiveness of such a two vasodilators and found that mecholyl produced less vasodilation. They also used histamine iontophoresis for patients with diverse ailments, particularly joint discomfort. The creators described reduced suffering and a broader range of motion. Because there was no change in joint swelling, it's possible that the improvements were due to a discomfort modification. Kling and Sashin also reported improvements in individuals with vasospasm-related illnesses, such as Raynaud's disease ⁹².

Other Disciplines: Clinical Applications Iontophoresis has been used in dentistry to a much greater extent than it has been used in active recovery. Before oral procedures, dental professionals began to connect their patients with local soporifics in the late 1800s. Gangarosa demonstrated the use of iontophoresis in dentistry for three primary purposes: treating overly sensitive dentin (e.g., in teeth sensitive to air and cold fluids) with negatively charged fluoride particles; treating oral ulcers (Canker Sores) and herpes or labialise sores ("fever rankles") with negatively charged corticosteroids and antiviral medications, respectively; and using nearby sedatives to deliver significant topical anesthesia. Gangarosa looked at how antiviral treatment for herpes labialis exacerbated the idoxuridine. He claimed that it is incredibly effective, with a repair duration of only 3-4 days (ordinary 9-10 days). There was a rapid loss of discomfort and a quickening of every subsequent phase of the pain, including the mix of vesicles, rapid overflowing, the emergence of that little scab, avoidance of injury spread, and speedy mending. Lichen planus is treated with methylprednisolone sodium succinate ⁹³.

Dermatology: Previously, basic particles and significant metals were the most often used medications, but interest has now shifted to iontophoresis as a medication conveyance framework for a wide range of treatments, ranging from steroids to anti-toxins to nearby sedatives ⁹⁴. Patients with hyperhidrosis of the palms, feet, and axillae have been treated with iontophoresis using tap water or anticholinergic mixtures. Iontophoresis has been used to treat contagious infections, viral contaminations, ulcers, aphthous stomatitis, lichen planus and anesthesia, among other dermatologic problems. There have been reports of hyperkeratosis treatment with fissuring of the palms and soles, vitiligo, scleroderma, lymphedema, fix testing and sweat testing. Copper sulphate, iodoxuridine and sodium salicylate have all been shown to be beneficial in treating dermatophytosis, herpes simplex and plantar moles ^95-97.

Otorhinolaryngology: Iontophoresis is a popular method for obtaining anesthesia of the tympanic film prior to basic procedures involving that structure in otorhinolaryngology. Zinc iontophoresis has also been used to treat patients with rhinitis who are genetically predisposed to it.

Ophthalmology: Iontophoresis has been used to deliver anti-toxins into the eye on a trial basis. The strategy's biggest disadvantage is the amount of time it takes for the direct contact of the anode with the eye is the strategy's biggest disadvantage ⁹⁸.

Iontophoresis Affecting Components:

Current: The current can be instantaneous, interchangeable, or beat-like, with waveforms such as square, sinusoidal, triangular, and trapezoidal. Because the instantaneous current is most commonly used, the more complicated structures may not be the best option. Exchanging current (air conditioning) iontophoresis resulted better than steady current DC iontophoresis in a current study. Consistent behavior when compared to typical steady current DC iontophoresis, AC iontophoresis showed less transition drift and skin-to-skin fluctuation ⁹⁹.

Variables in Physicochemistry: These include the medication's charge, size, structure, and lipophilicity. Water-soluble, low-portion, ionizable medicine with a full charge thickness is required. Iontophoresis is more versatile as atoms get smaller, but large particles can also be ion-tophoresable. Parts of the current, the physicochemical qualities of the drug, definition factors, organic elements, and the electroendoosmotic stream are all aspects that influence iontophoresis.

Factors in Planning: The focus of the drug, pH, ionic quality, and thickness are all factors to consider.

1. Drug Fixation: Increasing medicine concentrations increase medication delivery to a certain extent.
2. Ionic Quality: If cushion particles are included, they compete with the medication for delivery, reducing the amount of medication delivered, especially because cradle particles are often smaller and more adaptable than the larger dynamic medication.
3. pH: The pH of the configuration can be maintained by larger atoms, such as
4. Ethanolamine: instead of the more corrosive hydrochloric acid and sodium hydroxide, ethanolamine hydrochloride is used. The difficulty for the available current will increase as the ionic quality of the system improves, especially since dynamic drugs are typically more potent and present in a lower concentration than these accidental particles.
5. Viscosity: The consistency is not connected to the development of the drug.

Organic Ingredients: The thickness, porousness, and proximity of pores of the skin whereby the cathodes are linked are among these characteristics. Sweat organs are the most notable conduits for race transmission into the skin. This was demonstrated by Papa and Kligman, who used iontophoresis to introduce methylene blue into sweat organs in an interspersed pattern, laying out the sweat pores ¹⁰⁰.

CONCLUSION: Iontophoresis is among the most promising approaches for improving medicine delivery via the skin with a low saturation profile. Iontophoresis improves the velocity of the release of drug as well as the degree of salt type drug entry. Because of the hydrophobic nature of the skin, those charged species are unable to penetrate it via iontophoresis. Iontophoresis is becoming more widely used because it provides non-intrusive and useful means for organizing drugs with poor bioavailability profiles, short half-lives, and various dosing schedules. In comparison to an oral course, iontophoresis certainly provides benefits such as increased adequacy and reduced negative effects. In contrast to parenteral treatment, it is thought to be a more practical choice. The rate of medication information can be regulated and increased, which is one of the major advantages of the iontophoretic medicate conveyance framework. As a result, iontophoresis may soon become a viable alternative for medicine delivery.

ACKNOWLEDGEMENT: Authors are grateful to Vishwakarma University, Pune, India, for their eternal encouragement and endless support.

CONFLICTS OF INTEREST: The authors announce no conflict of interest, financial or otherwise.

REFERENCE:

1. Banga AK: Electrically assisted transdermal and topical drug delivery. USA Taylor and Francis Group First Edition 1998.
2. Wang Y, Thakur R, Fan Q and Michniak B: Transdermal iontophoresis: combination strategies to improve transdermal iontophoretic drug delivery. European Journal of Pharm Biopharm 2005; 60: 179–191.
3. Anal AK: Stimuli induced pulsatile or triggered release delivery systems for bioactive compounds. Recent Patents on Endocr Metabol Immune Drug Disc 2007; 1: 83-90.
4. Hilt JZ and Peppas NA: Microfabricated drug delivery devices. Internatio J of Pharmaceutics 2005; 306: 15-23.
5. Gupta P, Vermani K and Garg S: Hydrogels: from controlled release to pH-responsive drug delivery. Drug Discovery Today 2002; 7: 569-79.
6. Ahmad M and Hafeez A: Review Paper on Iontophoresis. Int J Res Pharm Sci 2021; 12(1): 344-348.
7. Roustit M and Blaise S: Trials and tribulations of skin iontophoresis in therapeutics. Br J Clin Pharmacol 2014; 77(1): 63–71.
8. Arunachalam S and Gunasekaran S: Diabetic research in India and China today: From literature-based mapping to health-care policy. Current Sciences 2002; 82: 1086–1097.
9. Manivannan A and McBain V: Ophthalmology. The Physiological Measurement Handbook. Chapter 2014; 12: 20.
10. Delgado-Charro MB: Iontophoretic drug delivery across the nail. Expert Opin Drug Deliv 2012; 9: 91–103.
11. Shahi S and Deshpande S: Iontophoresis: An approach to drug delivery enhancement. Int J Pharm Sci Res 2017; 8(10): 4056-68.
12. Calatayud-Pascual MA and Merino V: Influence of chemical enhancers and iontophoresis on the in-vitro transdermal permeation of propranolol: evaluation by dermatopharmacokinetics. Pharmaceutic 2018; 10(4): 265.
13. Kalaria DR, Dubey S and Kalia YN: Clinical Applications of Transdermal Iontophoresis. Topical and Transdermal Drug Delivery 2012; 3: 67–83.
14. Grant C and Fowler MD: Transcutaneous Electrical Nerve Stimulation, Phonophoresis and Iontophoresis. In Pfenninger and Fowler's Procedures for Primary Care 2020.
15. Robert L: Transdermal drug delivery: past progress, current status, and future prospects. Adv Drug Deliv Rev 2004; 56: 557–558.
16. Yogeshvar N, Naik A, Garrison J and Guy R: Iontophoretic drug delivery. Adv Drug Deliv Rev 2004; 56: 619–658.
17. Gratieri T, Santer V and Kalia YN: Basic principles and current status of transcorneal and transscleral iontophoresis. Expert Opinion on Drug Del 2016; 11: 1-12.
18. Guy RH and Marro D: Peptides and Proteins: Transdermal Absorption. In: James Swarbrick, ed. Encyclopedia of Pharmaceutical Technology. Marcel Dekker, Inc. New York Edition 2007; 3: 2741–2755.
19. Singh I and Prasanthi S: Percutaneous penetration enhancement in transdermal drug delivery. Asian Journal of Pharmaceutics 2010; 92–101.
20. Sanderson J and Riel S: Iontophoretic delivery of nonpeptide drugs: Formulation optimization for maximum skin permeability. J Pharm Sci 1989; 78: 361–364.
21. Noh G, Keum T and Seo J: Iontophoretic Transdermal Delivery of Human Growth Hormone (hGH) and the Combination Effect of a New Type Microneedle, Tappy Tok Tok®. Pharmaceutics 2018; 10(3): 153.
22. Herwadkar A and Banga AK: Peptide and protein transdermal drug delivery. Drug Discovery Today Technologies 2012; 9(2).
23. Publisher BS: Transdermal Iontophoresis. Current Technologies to Increase the Transdermal Delivery of Drugs 2012; 41-52.
24. Karpinski TM: Selected Medicines Used in Iontophoresis. Pharmaceutics 2018; 10(4): 204.
25. Sage BH: Iontophoresis. In: Swarbrick J, Boylan JC: Encyclopedia of Pharmaceutical Technology. Marcel Dekker, New York, Edition 1993; 2.
26. Singh P, Liu P and Dinh SM: Facilitated transdermal delivery by iontophoresis. In: Bronaugh RL, Maibach HI editors. Percutaneous Absorption, Drugs-Mechanisms-Methodology. Marcel Dekker New York 1999.
27. Junginger HE: iontophoretic delivery of apomorphine: from in-vitro modeling to the parkinson patient. Advanced Drug Delivery Review 2002; 54: 57-75.
28. Barry BW: Drug delivery routes in skin: a novel approach. Advanced Drug Delivery Review 2002; 54: 31–40.
29. Dixit N, Bali V, Baboota S, Ahuja A and Ali J: Iontophoresis - An Approach for Controlled Drug Delivery. A Review. Current Drug Delivery 2007; 4: 1-10.
30. Green PG, Flanagan M, Shroot B and Guy RH: Iontophoretic Drug Delivery. Marcel Dekker New York 1993.
31. Huang YY, Wu SM and Wang CY: Response Surface Method: A Novel Strategy to Optimize Iontophoretic Transdermal Delivery of Thyrotropin-releasing Hormone. Pharm Res 1996; 13: 547-552.
32. Makoto K, Toshio I and Kozo T: Evaluation of skin barrier function using direct current ii: effects of duty cycle, waveform, frequency and mode. Biol Pharm Bulletin 2002; 25(12): 1623-1628.
33. Stefania P, Tiziana P, Massimo G, Fabiola C, Simonetta V and Marco R: Transdermal Delivery of Heparin Using Pulsed Current Iontophoresis. Pharm Res 2006; 23(1): 114-20.
34. Clemessy M, Couarraze G, Bevan B and Puisieux F: Preservation of skin permeability during in-vitro iontophoretic experiments. IJP 1994; 101(3): 219-226.
35. Srinivasan V and Higuchi WI: A model for iontophoresis incorporating the effect of convective solvent flow. International Journal of Pharmaceutics 1990; 60: 133–198.
36. Singh P and Maibach HI: Iontophoresis in drug delivery: basic principles and applications. Crit Rev Ther Drug Carrier System 1994; 11: 161–213.
37. Krueger E and Scheeren EM: Iontophoresis: principles and applications. Fisioter Mov 2014; 27(3): 1-10.
38. Peter ME, Jui-Chen T and Gopinathan KM: Skin barrier and percutaneous drug delivery. In: Dermatology. Bolognia JL, Jorrizo JL, Rapini RP: London: Mosby, 2003; 1969- 8.
39. Pikal MJ: The role of electroosmotic flow in transdermal iontophoresis. Advanced Drug Delivery Review 2001; 46: 281-305.
40. Zhu HG, Li SK, Peck KD, Miller DJ and Higuchi WI: Journal of Controlled Release 2002; 82: 249.
41. Shibaji T, Yasuhara Y, Oda N and Umino M: A mechanism of high frequency AC iontophoresis. Journal of Controlled Release 2001; 73: 37.
42. Sahota TS, Latham RJ, Linford RG and Taylor PM: Iontophoretic Drug Delivery using Polymer Electrolyte Materials: A Review. Drug Development and Industrial Pharmacy 1999; 25: 307.
43. Sahota TS, Latham RK, Linford RG and Taylor PM: Drug Development and Industrial Pharmacy 2000; 26: 1039.
44. Risbud MV, Hardikar AA, Bhat SV and Bhonde RR: pH-sensitive freeze-dried chitosan-polyvinyl pyrrolidone hydrogels as controlled release system for antibiotic delivery. Journal of Controlled Release 2000; 68: 23.
45. Ma GH, Nagai M and Omi S: Study on preparation of monodispersed poly (styrene co N-dimethyl amino ethyl methacrylate) composite microspheres by SPG (Shirasu Porous Glass) emulsification technique. Journal of Applied Polymer Science 2001; 79: 2408.
46. Yaung JF and Kwei TK: Studies of temperature influence on volatile thermal degradation products of poly(ethylene terephthalate). Journal of Applied Polymer Science 1998; 69: 2377–2381.
47. Fang JY, Sung KC, Lin HH and Fang CL: Transdermal iontophorsis delivery of diclofenac sodium from various polymer formulation: in-vitro and in-vivo. International Journal of Pharmaceutics 1999; 178: 83-92.
48. Masci G, Husu I, Murtas S, Piozzi A and Crescenzi V: Physical Hydrogels of Poly (vinyl alcohol) with Different Syndiotacticity Prepared in the Presence of Lactosilated Chitosan Derivatives. Macromolecular Bioscience 2003; 3: 455-461.
49. Bajpai AK and Bhanu S: In-vitro release dynamics of insulin from a loaded hydrophilic polymeric network. Journal of Materials Science: Materials in Medicine 2004; 15: 43-54.
50. Green P and Flalagan M: Iontophoretic drug delivery system. In: Walters KA, Hadgraft J: Pharmaceutical Skin Penetration Enhancement, Marcel Dekker New York 1996; 100–124.
51. Green P, Flanagan M and Shroot B: Iontophoretic drug delivery. Marcel Dekker Inc New York 1993; 311–333.
52. Chaturvedula A, Joshi DP, Anderson C, Morris RL, Sembrowich WL and Banga AK: In-vivo iontophoretic delivery and pharmacokinetics of salmon calcitonin. International Journal of Pharmaceutics 2005; 297: 190–196.
53. Masada T, Higuchi W, Behl C and Srinivasan V: Examination of iontophoretic transport of ionic drugs across skin: baseline studies with the four-electrode system. International J of Pharmaceutics 1989; 49: 57–62.
54. Charro D and Guy M: Iontophoresis of peptides. In: Electronically Controlled Drug Delivery. Berner B, Dinh SM; eds. CRC Press: Boca Raton 1998; 129–157.
55. Cullander C: What are the pathways of iontophoretic current flow through mammalian skin. Advanced Drug Delivery Review 1992; 9: 119–135.
56. Singh J and Bahtia K: Topical iontophoretic drug delivery, Pathways, principles, factors and skin irritation. Med Res Rev 1996; 16: 285–296.
57. Siddiqui O, Roberts M and Polock A: The effect of iontophoresis and vehicle pH on the in-vitro permeation of lignocaine through human stratum corneum. Journal of Pharm Pharmacology 1985; 37: 732–735.
58. Anderson CR, Morris RL, Boeh SD, Panus PC and Sembrowich WL: Effects of Iontophoresis Current Magnitude and Duration on Dexamethasone Deposition and Localized Drug Retention. Phys Ther 2003; 83: 161–170.
59. Pikal M: Transport mechanisms in iontophoresis: A theoretical model for the effect of electro osmotic flow on flux enhancement in transdermal iontophoresis. Pharm Res 1990; 7: 118–126.
60. Pikal M and Shah S: Transport mechanisms in iontophoresis: Electro osmotic flow and transference number measurements for hairless mouse skin. Pharm Res 1990; 7: 213-221.
61. Pikal M and Shah S: Transport mechanisms in iontophoresis: An experimental study of the contributions of electro osmotic flow and permeability change in transport of low and high molecular weight solutes. Pharm Res 1990; 7: 222–229.
62. Cevc G, Gebauer D, Stieber J, Schätzlein A and Blume G: Ultra flexible vesicles, transferosomes have an extremely low pore penetration resistance and transport therapeutic amount of insulin across the intact mammalian skin. Biochem Biophys Acta 1995; 136: 201–215.
63. Cullander C and Guy R: Sites of iontophoretic current flow into the skin: identification and characterization with the vibrating probe electrode. J Invest Dermatol 1991; 97: 55–64.
64. Del T, Bhel C and Nash R: Iontophoretic transport of a homologues series of ionized and nonionized model compounds: Influence of Hydrophobicity and mechanistric interpretation. Pharm Res 1989; 6: 85–90.
65. Dixit N, Baboota S, Ahuja A and Ali J: Iontophoresis-An Approach for Controlled Drug Delivery: A Review. Current Drug Delivery 2007; 4: 1–10.
66. Bronaugh R and Maibach H: Percutaneous Absorption: Mechanisms–Methodology–Drug Delivery. Marcel Dekker, New York and Basel 1989; 150–163.
67. Burnette R: Transdermal Drug Delivery. Marcel Dekker, New York 1988; 45–63: 202–246.
68. Patrizia S and Richard H: Reverse iontophoresis-parameters determining electroosmotic flow. II. Electrode chamber formulation. J of Control Relea 1996; 42: 29–36.
69. Tierney MJ, Potts RO and Tamada JA: Glucose monitoring by reverse iontophoresis. Diabetes Metab Res Rev 2002; 18: 49–53.
70. Huang JF, Sung KC, Hu OY, Wang JJ, Lin YH and Fang JY: The effects of electrically assisted methods on transdermal delivery of nalbuphine benzoate and sebacoyl dinalbuphine ester from solutions and hydrogels. International J of Pharmaceutics 2005; 297: 162–271.
71. Prausnitz MR, Bose VG and Langer R: Electroprotion of mamalia on skin. A mechanism to enhance transdermal drug delivery. Proc Nat Acad Sci USA 1993; 90: 10504–10508.
72. Banga AK, Bose S and Ghosh TK: Iontophoresis and electroporation: comparisons and contrasts. International Journal of Pharmaceutics 1999; 179: 1–19.
73. Marro D and Guy R: Characterization of the iontophoretic per selectivity properties of human and pig skin. Journal of Controlled Release 2000; 70: 213–217.
74. Chien YW: Development of Transdermal drug delivery systems. Drug Development and Industrial Pharmacy 1987; 13: 589–651.
75. Mishra AN: Transdermal drug delivery. In: Jain NK, ed. Controlled and Novel Drug Delivery. Varghese Publication New Delhi, Edition 1998; 100–129.
76. Ritschel WA and Hussain AS: The principles of skin permeation. Meth Find Exptl Clin Pharm 1988; 10: 39–56.
77. Brain KR, Walters KA and Watkinson AC: Methods for studying percutaneous absorption. In: Walters KA, ed. Dermatological and transdermal formulations. Marcel Dekker Inc. New York 2002; 241–247.
78. Wanga Y, Thakura R, Fanb Q and Michank B: Transdermal iontophoresis: combination strategies to improve transdermal iontophoretic drug delivery. European J of Pharma and Biopharmac 2005; 60: 180.
79. Vikram K, Kiran B and Rahul T: Enhancement of Iontophoretic Transport of Diphenhydramine Hydrochloride Thermosensitive Gel by Optimization of pH, Polymer Concentration, Electrode Design and Pulse rate. Pharm Sci Tech 2007; 8: 1-6.
80. Stamatialis DF, Rolevink HH, Gironès M, Nymeijer DC and Koops GH: In-vitro evaluation of a hydroxypropyl cellulose gel system for transdermal delivery of timolol. Current Drug Delivery 2004; 1: 313-319.
81. Rios M: Advances in trasnsdermal technologies. Pharm Tech 2007; 31: 10.
82. Holzle E and Ruzicka T: Treatment of hyperhidrosis by a battery-operated iontophoretic device. Dermatologica 1986; 172: 41-47.
83. Sloan JB and Soltani K: lontophoresis in dermatology. J Am Acad Dermatol 1986; 15: 671-84.
84. Webster HL: Laboratory diagnosis of cystic fibrosis. Crit Rev Clin Lab Sci 1983; 18: 313-338.
85. Gangarosa LP: Defining a practical solution for iontophoretic local anesthesia. Methods Find Exp Clin Pharmacol 1981; 3: 83-94.
86. Glass JM, Stephen RL and Jacobsen SC: The quantity and distribution of radio labeled dexamethasone delivered to tissue by iontophoresis. Inte J of Derma 1980; 19: 519-25.
87. Murray W, Lavinc LS and Scifter E: The iontophoresis of C21 esteritied glucocorticoids: preliminary report. J Am Phy Thei Assoc 1963; 43: 579-581.
88. Kahn J: Iontophoresis and Ultrasound for postsurgical temporomandibular trismus and paresthesia. Phys Ther 1980; 60: 307-308.
89. Rothfield SH and Murray W: The treatment of Peyronie’s disease by iontophoresis of esterified glucocorticoids Journal of Urol 1967; 97: 874-75.
90. Magistro CM: Hyaluronidase by iontophoresis in the treatment of edema. Phys Ther 1964; 44: 169-175.
91. Popkin R. The use of hyaluronidase by iontophoresis in the treatment of generalized scleroderma. J Invest Dermatol 1951; 16: 97-102.
92. Yoshida NH and Roberts MS: Structure transport relationships in transdermal iontophoresis. Advanced Drug Delivery Review 1992; 9: 239-264.
93. Sachdeva S, Gupta R and Gupta G: Iontophoresis and Dentistry. The Journal of the Indian Dental Association 2011; 5: 46-48.
94. Rai R, Srinivas CR: Iontophoresis in dermatology. Indian J of Dermatology Venereol Leprol 2005; 71: 236-241.
95. Jersild O and Plesner N: Treatment of epidermatophytosis in the extremities in the extremities with iontophoresis of copper. Acta Dermato-Venereologica 1940; 21: 268-279.
96. Gangarosa LP, Merchant HW, Park NH and Hill JM: Iontophoretic application of iodoxuridine for recurrent herpes labialis: Report of preliminary clinical findings. Methods Find Exp Clin Pharmacol 1979; 105-109.
97. Gordan NH and Weinstein MV: Sodium salicylate iontophoresis in the treatment of plantar warts (a case report). Phys Ther 1969; 49: 869-870.
98. Costello CT and Jeske AH: Iontophoresis applications in transdermal medication delivery. Ph The 1995; 75: 554-63.
99. Zhu H, Li SK, Peck KD, Miller DJ and Higuchi WI: Improvement on conventional constant current DC Iontophoresis: Study using constant conductance AC Iontophoresis. J Control Release 2002; 82: 249-61.
100. Papa CM and Kligman AM: Mechanism of eccrine anhidrotic. Journal of Invest Dermatology 1966; 47: 1-9.
     

     ---

     How to cite this article:

     Bagade OM and Doke PE: Fundamental principle and applications of iontophoresis in contemporary advancement of drug delivery system: a critical appraisal. Int J Pharm Sci & Res 2022; 13(10):3883-99. doi: 10.13040/IJPSR.0975-8232.13(10).3883-99.

     ---

     All © 2022 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.